Google AI founder placed on leave

Amy Baxter | | Health Exec | Economics

A co-founder of Google’s AI business DeepMind has been placed on leave following controversy over some of his projects, Bloomberg reported.

DeepMind has already developed several important clinical uses for AI technology, including aiding in screening for future acute kidney injuries, identifying eye diseases and working with the VA to predict patient deterioration.

Its co-founder, Mustafa Suleyman, who runs the applied division of DeepMind, is also a high-profile executive and public speaker. He also developed the 100-person DeepMind Health team. A DeepMind spokeswoman did not tell Bloomberg why Suleyman was put on leave.

DeepMind has received criticism for some of its work in the U.K., with accusations that the company illegally obtained millions of patient records, according to Bloomberg. Since then, DeepMind Health has been folded into Google Health.

See the full story below:

Google DeepMind Co-Founder Placed on Leave From AI Lab

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.